Physician profile
Charles E Geringer
NPI 1235195702
$18,838.59
in general payments reported to CMS, 2019-2025
38 companies · $3,333 in 2025
The $3,333 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,134 · 2020: $1,434 · 2021: $1,788 · 2022: $3,067 · 2023: $3,467 · 2024: $2,615 · 2025: $3,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,268 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,267.61 |
| Education | $147.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,630.51 | 2019-2025 | Enbrel, Krystexxa, Evenity |
| Pfizer INC. | $2,726.41 | 2019-2025 | |
| Abbvie INC. | $2,644.32 | 2019-2025 | |
| Janssen Biotech, INC. | $1,273.44 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,052.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $799.66 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $665.06 | 2019-2024 | Cyltezo, Ofev |
| Horizon Therapeutics Plc | $609.39 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $580.87 | 2021-2025 | Saphnelo, Evusheld |
| Lilly USA, LLC | $493.24 | 2019-2025 | Taltz, Olumiant |
| Mallinckrodt Hospital Products INC. | $454.54 | 2020-2024 | Acthar |
| Glaxosmithkline, LLC. | $428.05 | 2019-2025 | Benlysta |
| Actelion Pharmaceuticals US, INC. | $388.24 | 2021-2025 | Opsumit, Uptravi |
| Ucb, INC. | $383.53 | 2019-2025 | Bimzelx, Cimzia |
| Celgene Corporation | $334.40 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $327.03 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $264.12 | 2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $255.53 | 2020-2025 | Strensiq |
| Kyowa Kirin, INC. | $174.51 | 2023-2025 | Crysvita |
| Antares Pharma, INC. | $145.08 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $138.30 | 2023-2025 | Idacio, Tyenne |
| Mallinckrodt Enterprises LLC | $118.26 | 2019 | |
| Genzyme Corporation | $105.09 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $99.84 | 2021 | |
| Sobi, INC | $95.71 | 2020-2024 | |
| Ultragenyx Pharmaceutical INC. | $93.92 | 2020-2022 | |
| Genentech USA, INC. | $84.53 | 2019-2024 | Actemra, Rituxan |
| Merck Sharp & Dohme LLC | $68.22 | 2019-2020 | |
| Organon LLC | $67.41 | 2021-2024 | Hadlima, Renflexis |
| Medexus Pharma, INC. | $62.39 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $50.14 | 2021-2024 | Lupkynis |
| Sandoz INC. | $48.22 | 2023-2024 | Hyrimoz |
| Biocon Biologics INC | $41.70 | 2024 | Hulio |
| Zyla Life Sciences, INC. | $41.52 | 2019-2020 | |
| Mylan Institutional INC. | $35.26 | 2023 | Hulio |
| Kiniksa Pharmaceuticals, Ltd. | $24.34 | 2021-2022 | |
| Celltrion USA INC. | $16.95 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals International, Plc | $16.28 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Geringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.